Adaptimmune Therapeutics PLC ADR sell mixitrader
Start price
18.10.20
/
50%
€5.70
Target price
04.11.21
€2.00
Performance (%)
-35.79%
End price
26.06.21
€3.66
Summary
This prediction ended on 26.06.21 with a price of €3.66. mixitrader correctly predicted massive losses of -35.79% for Adaptimmune Therapeutics PLC ADR. mixitrader has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Adaptimmune Therapeutics PLC ADR | 10.769% | 10.769% | 43.046% | -70.330% |
iShares Core DAX® | 1.665% | 0.362% | 17.556% | 15.301% |
iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% | 36.536% |
iShares Nikkei 225® | 2.620% | 1.174% | 17.273% | 10.880% |
iShares S&P 500 | -0.091% | -1.597% | 24.739% | 36.919% |
According to mixitrader what are the pros and cons of Adaptimmune Therapeutics PLC ADR for the foreseeable future?
Pros
Cons
Probably not worthwhile Investment
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected
negative Cash Flow expected
Bad rating
Little Investments for future growth
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Below average Management
Bad culture
Little innovation
Few uniques
Dependend from some customers or products
Growths slower than the competition
Sustainability is little important
Higher risks for its business
Below average Marketposition
Little known brand
Business model of the past or high risk
Revenue decline/stagnation expected
high free float
Significant cyclical dependencies
Comments by mixitrader for this prediction
In the thread Adaptimmune Therapeutics PLC ADR diskutieren
Sell mit Kursziel 2,0
In the thread Trading Adaptimmune Therapeutics PLC ADR
Sell beendet
Stopped prediction by mixitrader for Adaptimmune Therapeutics PLC ADR
Adaptimmune Therapeutics PLC ADR
Start price
Target price
Perf. (%)
€1.10
06.07.24
06.07.24
€2.00
06.07.25
06.07.25
0.00%
21.07.24
21.07.24
Probably not worthwhile Investment
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation